Ovid Therapeutics (OVID) Net Margin (2020 - 2025)
Ovid Therapeutics (OVID) posted Net Margin of 1345.82% for Q4 2025, up 114.61% on a QoQ basis from 9210.61% in Q3 2025, and up 1352082.0% year-over-year from N/an in Q4 2024.
Ovid Therapeutics (OVID) Net Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics' Net Margin history runs 6 years deep, the most recent figure standing at 1345.82% for Q4 2025.
- Quarterly Net Margin rose 1352082.0% year-over-year to 1345.82% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 339.33% (up 421779.0% YoY) and the FY2025 annual result came in at 240.13%, up 443001.0% from the prior year.
- Net Margin was 1345.82% for Q4 2025 at Ovid Therapeutics, up from 9210.61% in the prior quarter.
- Across five years, Net Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.33% in Q3 2022.
- A 5-year average of 14407.79% and a median of 8653.28% in 2024 frame the typical range for Net Margin.
- Peak annual rise in Net Margin reached 9747448 bps in 2023, while the deepest fall reached 1912190 bps in 2023.
- Ovid Therapeutics' Net Margin stood at 84.46% in 2021, then sank by 29532 bps to 24859.09% in 2022, then soared by 57 bps to 10790.14% in 2023, then slipped by 13 bps to 12175.0% in 2024, then soared by 111 bps to 1345.82% in 2025.
- Business Quant data shows OVID's Net Margin at 1345.82% in Q4 2025, 9210.61% in Q3 2025, and 74.68% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | - |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 30.33% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 17.65% |
| 10 | Ovid Therapeutics | 119.41 Mn | -36.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,345.82% |
| Sep 30, 2025 | -9,210.61% |
| Jun 30, 2025 | -74.68% |
| Mar 31, 2025 | -7,873.08% |
| Dec 31, 2024 | -12,175.00% |
| Sep 30, 2024 | -8,095.95% |
| Jun 30, 2024 | 5,042.01% |
| Mar 31, 2024 | -7,901.35% |
| Dec 31, 2023 | -10,790.14% |
| Sep 30, 2023 | -10,323.85% |
| Jun 30, 2023 | -16,544.00% |
| Mar 31, 2023 | -20,236.36% |
| Dec 31, 2022 | -24,859.09% |
| Sep 30, 2022 | -107,798.33% |
| Mar 31, 2022 | -1,114.46% |
| Mar 31, 2021 | 84.46% |
| Dec 31, 2020 | -386.27% |
| Sep 30, 2020 | -237.56% |